

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Single Technology Appraisal (STA)

Aflibercept for treating visual impairment caused by macular oedema secondary to branch retinal vein occlusion [ID844]

#### Matrix of Consultees and Commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Bayer (aflibercept)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Blind People</li> <li>• Eyecare Trust</li> <li>• Fight for Sight</li> <li>• Macular Society</li> <li>• Muslim Council of Britain</li> <li>• OBAC</li> <li>• Royal National Institute of Blind People (RNIB)</li> <li>• SeeAbility</li> <li>• Sense</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Thomas Pocklington Trust</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Geriatrics Society</li> <li>• British Ophthalmic Anaesthesia Society</li> <li>• College of Optometrists</li> <li>• Oxford Eye Foundation</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Ophthalmologists</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Merton CCG</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• Allergan (dexamethasone intravitreal implant)</li> <li>• Coherent UK (photocoagulation)</li> <li>• Litechnica (photocoagulation)</li> <li>• Liverpool and Broadgreen University Hospitals Pharmacy (bevacizumab)</li> <li>• Lumenis UK (photocoagulation)</li> <li>• Moorfields Pharmaceuticals (bevacizumab)</li> <li>• Novartis Pharmaceuticals (ranibizumab)</li> <li>• Quantel Medical (photocoagulation)</li> <li>• Topcon Great Britain (photocoagulation)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Eyes and Vision Group</li> <li>• Eye Hope</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• NHS Trafford CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Institute of Ophthalmology, University College London</li> <li>• MRC Clinical Trials Unit</li> <li>• National Eye Research Centre Charity</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.